Outlook Therapeutics (OTLK) Competitors $1.53 -0.02 (-1.29%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.53 0.00 (0.00%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. CRDF, IVA, FULC, BTMD, SOPH, GOSS, ANNX, HURA, DBVT, and PRMEShould you be buying Outlook Therapeutics stock or one of its competitors? The main competitors of Outlook Therapeutics include Cardiff Oncology (CRDF), Inventiva (IVA), Fulcrum Therapeutics (FULC), biote (BTMD), SOPHiA GENETICS (SOPH), Gossamer Bio (GOSS), Annexon (ANNX), TuHURA Biosciences (HURA), DBV Technologies (DBVT), and Prime Medicine (PRME). These companies are all part of the "pharmaceutical products" industry. Outlook Therapeutics vs. Cardiff Oncology Inventiva Fulcrum Therapeutics biote SOPHiA GENETICS Gossamer Bio Annexon TuHURA Biosciences DBV Technologies Prime Medicine Outlook Therapeutics (NASDAQ:OTLK) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, community ranking, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Is OTLK or CRDF more profitable? Outlook Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. Outlook Therapeutics' return on equity of 0.00% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Outlook TherapeuticsN/A N/A -225.12% Cardiff Oncology -6,238.17%-73.97%-60.40% Does the media favor OTLK or CRDF? In the previous week, Cardiff Oncology had 3 more articles in the media than Outlook Therapeutics. MarketBeat recorded 4 mentions for Cardiff Oncology and 1 mentions for Outlook Therapeutics. Outlook Therapeutics' average media sentiment score of 1.89 beat Cardiff Oncology's score of 0.91 indicating that Outlook Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Outlook Therapeutics Very Positive Cardiff Oncology Positive Which has better earnings & valuation, OTLK or CRDF? Cardiff Oncology has higher revenue and earnings than Outlook Therapeutics. Cardiff Oncology is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOutlook TherapeuticsN/AN/A-$75.37M-$7.42-0.21Cardiff Oncology$683K280.51-$41.44M-$0.94-3.06 Do insiders and institutionals hold more shares of OTLK or CRDF? 11.2% of Outlook Therapeutics shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 4.8% of Outlook Therapeutics shares are held by insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, OTLK or CRDF? Outlook Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Do analysts recommend OTLK or CRDF? Outlook Therapeutics presently has a consensus target price of $10.20, indicating a potential upside of 566.67%. Cardiff Oncology has a consensus target price of $11.67, indicating a potential upside of 305.09%. Given Outlook Therapeutics' higher possible upside, equities research analysts plainly believe Outlook Therapeutics is more favorable than Cardiff Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Outlook Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OTLK or CRDF? Outlook Therapeutics received 123 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 71.12% of users gave Outlook Therapeutics an outperform vote while only 64.62% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformOutlook TherapeuticsOutperform Votes16571.12% Underperform Votes6728.88% Cardiff OncologyOutperform Votes4264.62% Underperform Votes2335.38% SummaryCardiff Oncology beats Outlook Therapeutics on 9 of the 17 factors compared between the two stocks. Get Outlook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOutlook TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.99M$2.89B$5.46B$7.72BDividend YieldN/A1.89%5.42%4.25%P/E Ratio-0.2129.7522.4518.49Price / SalesN/A484.79392.19101.64Price / CashN/A168.6838.1834.62Price / Book-0.973.036.684.19Net Income-$75.37M-$72.17M$3.22B$248.18M7 Day Performance4.08%8.04%6.32%7.02%1 Month Performance15.91%-2.70%-1.09%0.33%1 Year Performance-81.85%-20.81%16.80%4.70% Outlook Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOutlook Therapeutics1.836 of 5 stars$1.53-1.3%$10.20+566.7%-81.9%$48.99MN/A-0.2120Positive NewsCRDFCardiff Oncology1.2833 of 5 stars$2.82-1.1%$11.67+313.7%-29.2%$187.60M$683,000.00-3.0020Upcoming EarningsIVAInventiva1.95 of 5 stars$3.56+6.0%$10.40+192.1%+19.7%$186.82M$9.20M0.00100Gap UpFULCFulcrum Therapeutics1.8187 of 5 stars$3.46+5.2%$8.63+149.3%-50.6%$186.77M$80M-11.16100Positive NewsBTMDbiote3.8279 of 5 stars$3.41+3.3%$8.00+134.6%-37.9%$186.56M$197.19M13.12194Positive NewsSOPHSOPHiA GENETICS2.4401 of 5 stars$2.78-1.8%$6.80+144.6%-37.2%$185.39M$65.17M-2.55520GOSSGossamer Bio3.9616 of 5 stars$0.81-3.5%$7.50+822.5%+43.5%$184.73M$114.70M-2.54180Positive NewsANNXAnnexon2.016 of 5 stars$1.68+15.1%$18.67+1,011.1%-60.0%$184.31MN/A-1.6060Positive NewsHURATuHURA BiosciencesN/A$4.20+1.2%$12.67+201.6%N/A$183.46MN/A0.00N/APositive NewsDBVTDBV Technologies3.5114 of 5 stars$8.91+11.7%$22.50+152.5%+25.1%$183.30M$15.73M-1.9880Short Interest ↓Positive NewsGap DownPRMEPrime Medicine2.4097 of 5 stars$1.39+12.1%$13.38+862.2%-61.8%$182.31M$2.98M-0.68234High Trading Volume Related Companies and Tools Related Companies Cardiff Oncology Competitors Inventiva Competitors Fulcrum Therapeutics Competitors biote Competitors SOPHiA GENETICS Competitors Gossamer Bio Competitors Annexon Competitors TuHURA Biosciences Competitors DBV Technologies Competitors Prime Medicine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 4/28/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored‘Wheels Are Falling Off’ the U.S. Stock MarketThe last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OTLK Stock Free OTLK Stock Alerts